Inertia For Supply Chain Change May Stick Even If BIOSECURE Fails

Efforts to de-risk the pharma supply chain’s reliance on China likely will not completely disappear if the BIOSECURE proposal dies.

close up of Asia on world map
Pharma supply chains may continue diversifying their supply chains even without the BIOSECURE legislation. (Shutterstock)
Key Takeaways
  • The BIOSECURE Act was left out of the National Defense Authorization Act despite attempts at a last-minute compromise, leaving a difficult road for the legislation to be enacted in 2024.

Pharma supply chains still may feel some long-lasting impacts from the proposed BIOSECURE Act, even though the bill appears unlikely to be enacted this year or perhaps ever, although it probably is too soon to assess them.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Distribution/Supply Chain

More from Geography